Tumor necrosis factor-alpha (TNF-α) inhibitors such as infliximab and adalimumab have shown mixed results, with many patients experiencing significant improvement in intestinal and osteoarticular disease but others developing paradoxical skin reactions such as new-onset psoriasis or exacerbated hidradenitis suppurativa [59,60]. Here, TNF is linked to psoriasis.